Five Prime Therapeutics (FPRX) Posts Q4 Loss of 55c/Share

Five Prime Therapeutics (NASDAQ: FPRX) reported Q4 EPS of ($0.55), $0.45 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $4.65 million versus the consensus estimate of $12.4 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c